TY - JOUR
T1 - Treatment of prostate cancer with regional lymph node (N1) metastasis
AU - Pollack, Alan
AU - Horwitz, Eric M.
AU - Movsas, Ben
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2003/4
Y1 - 2003/4
N2 - Prostate cancer with pathologically documented regional lymph node positive disease has been associated with a dismal prognosis in the past. Clinical and/or biochemical progression is evident within 5 years in over 50% treated with external-beam radiotherapy (EBRT) alone, radical prostatectomy (RP) alone, or androgen deprivation (AD) alone. By 10 years after treatment, greater than 75% progress and over half succumb to prostate cancer. In contrast, the results with the combination of EBRT + AD or RP + AD have been very promising. Ten-year biochemical progression and overall survival rates are roughly 20% and 70%, respectively, for patients with subclinical lymph node involvement. Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP.
AB - Prostate cancer with pathologically documented regional lymph node positive disease has been associated with a dismal prognosis in the past. Clinical and/or biochemical progression is evident within 5 years in over 50% treated with external-beam radiotherapy (EBRT) alone, radical prostatectomy (RP) alone, or androgen deprivation (AD) alone. By 10 years after treatment, greater than 75% progress and over half succumb to prostate cancer. In contrast, the results with the combination of EBRT + AD or RP + AD have been very promising. Ten-year biochemical progression and overall survival rates are roughly 20% and 70%, respectively, for patients with subclinical lymph node involvement. Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP.
UR - http://www.scopus.com/inward/record.url?scp=0037629107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037629107&partnerID=8YFLogxK
U2 - 10.1016/S1053-4296(03)70005-8
DO - 10.1016/S1053-4296(03)70005-8
M3 - Review article
C2 - 12728441
AN - SCOPUS:0037629107
VL - 13
SP - 121
EP - 129
JO - Seminars in Radiation Oncology
JF - Seminars in Radiation Oncology
SN - 1053-4296
IS - 2
ER -